Skip to main content
NewslettersWatchlist

Diagnos Inc(ADK-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.310
Day High0.330
Open:0.330
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
AI-generated - The Globe and Mail
Diagnos: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ADK)
GlobeNewswire
DIAGNOS Announces Closing of Private Placement
GlobeNewswire
DIAGNOS Announces the Engagement of Market Maker Consultant
GlobeNewswire
DIAGNOS Announces Grant of Stock Options
AI-generated - The Globe and Mail
Diagnos: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ADK)
GlobeNewswire
DIAGNOS Announces Voting Results of Meeting of Shareholders
GlobeNewswire
DIAGNOS Announces Variation in One Insider Ownership
GlobeNewswire
DIAGNOS Announces Closing of Private Placement
GlobeNewswire
DIAGNOS Announces Date of Annual General and Special Meeting of Shareholders
GlobeNewswire
DIAGNOS Successfully Completes ISO 13485 / MDSAP Audit and receives its certification to move forward with FDA and Health Canada
AI-generated - The Globe and Mail
Diagnos: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ADK)
GlobeNewswire
DIAGNOS Announces Closing of Second and Final Tranche of Private Placement
GlobeNewswire
DIAGNOS celebrates the launch of Labtician’s new screening service for diabetic retinopathy in Ontario and renews its distribution agreement
GlobeNewswire
DIAGNOS Announces Closing of First Tranche of Private Placement
GlobeNewswire
DIAGNOS to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024
GlobeNewswire
DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification
GlobeNewswire
DIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11th
GlobeNewswire
DIAGNOS Announces Grant of Stock Options
GlobeNewswire
DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors
GlobeNewswire
DIAGNOS Announces Closing of Second and Final Tranche of Private Placement
GlobeNewswire
DIAGNOS Announces Grant of Stock Options
GlobeNewswire
DIAGNOS Welcomes Mr. Michael Braeuel to its Board of Directors

Profile

Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in the business segment of Healthcare services. The company has a business presence in Canada, the United States, Mexico, Chile, and others. The company's key revenue is derived from Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.